ERBB2 and breast carcinoma: Using a tumor-informed ctDNA test, Lipsyc-Sharf et al. could show in patients with hormone receptor positive and HER2 negative breast cancer patients five years after completion of primary therapy, that 10% (n = 8) were ctDNA positive [16].